129 related articles for article (PubMed ID: 20413313)
1. Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: Synthesis and evaluation of their phosphodiesterase 4 inhibitory activity.
Biagini P; Biancalani C; Graziano A; Cesari N; Giovannoni MP; Cilibrizzi A; Dal Piaz V; Vergelli C; Crocetti L; Delcanale M; Armani E; Rizzi A; Puccini P; Gallo PM; Spinabelli D; Caruso P
Bioorg Med Chem; 2010 May; 18(10):3506-17. PubMed ID: 20413313
[TBL] [Abstract][Full Text] [Related]
2. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
[TBL] [Abstract][Full Text] [Related]
3. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.
Kim I; Song JH; Park CM; Jeong JW; Kim HR; Ha JR; No Z; Hyun YL; Cho YS; Sook Kang N; Jeon DJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):922-6. PubMed ID: 20053559
[TBL] [Abstract][Full Text] [Related]
5. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
Giovannoni MP; Vergelli C; Biancalani C; Cesari N; Graziano A; Biagini P; Gracia J; Gavaldà A; Dal Piaz V
J Med Chem; 2006 Aug; 49(17):5363-71. PubMed ID: 16913726
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.
Giovannoni MP; Cesari N; Graziano A; Vergelli C; Biancalani C; Biagini P; Dal Piaz V
J Enzyme Inhib Med Chem; 2007 Jun; 22(3):309-18. PubMed ID: 17674813
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors.
Kagayama K; Morimoto T; Nagata S; Katoh F; Zhang X; Inoue N; Hashino A; Kageyama K; Shikaura J; Niwa T
Bioorg Med Chem; 2009 Oct; 17(19):6959-70. PubMed ID: 19744860
[TBL] [Abstract][Full Text] [Related]
8. SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
Duplantier AJ; Bachert EL; Cheng JB; Cohan VL; Jenkinson TH; Kraus KG; McKechney MW; Pillar JD; Watson JW
J Med Chem; 2007 Jan; 50(2):344-9. PubMed ID: 17228876
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of some pyrazolo[3,4-d]pyridazinones and analogues as PDE 5 inhibitors potentially useful as peripheral vasodilator agents.
Dal Piaz V; Castellana MC; Vergelli C; Giovannoni MP; Gavaldà A; Segarra V; Beleta J; Ryder H; Palacios JM
J Enzyme Inhib Med Chem; 2002 Aug; 17(4):227-33. PubMed ID: 12530475
[TBL] [Abstract][Full Text] [Related]
10. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
Dal Piaz V; Giovannoni MP; Castellana C; Palacios JM; Beleta J; Doménech T; Segarra V
J Med Chem; 1997 May; 40(10):1417-21. PubMed ID: 9154964
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
Allcock RW; Blakli H; Jiang Z; Johnston KA; Morgan KM; Rosair GM; Iwase K; Kohno Y; Adams DR
Bioorg Med Chem Lett; 2011 Jun; 21(11):3307-12. PubMed ID: 21530250
[TBL] [Abstract][Full Text] [Related]
13. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Hamblin JN; Angell TD; Ballantine SP; Cook CM; Cooper AW; Dawson J; Delves CJ; Jones PS; Lindvall M; Lucas FS; Mitchell CJ; Neu MY; Ranshaw LE; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2008 Jul; 18(14):4237-41. PubMed ID: 18539455
[TBL] [Abstract][Full Text] [Related]
14. Cyclic nucleotide phosphodiesterase type 4 inhibitors: evaluation of pyrazolo[1,5-a]-1,3,5-triazine ring system as an adenine bioisostere.
Raboisson P; Schultz D; Muller C; Reimund JM; Pinna G; Mathieu R; Bernard P; Do QT; Desjarlais RL; Justiano H; Lugnier C; Bourguignon JJ
Eur J Med Chem; 2008 Apr; 43(4):816-29. PubMed ID: 17640774
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of pyrazolo[3,4-b]pyridines and its structural analogues as TNF-alpha and IL-6 inhibitors.
Bharate SB; Mahajan TR; Gole YR; Nambiar M; Matan TT; Kulkarni-Almeida A; Balachandran S; Junjappa H; Balakrishnan A; Vishwakarma RA
Bioorg Med Chem; 2008 Aug; 16(15):7167-76. PubMed ID: 18625560
[TBL] [Abstract][Full Text] [Related]
16. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
17. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
[TBL] [Abstract][Full Text] [Related]
18. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
19. Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha.
Cottam HB; Shih H; Tehrani LR; Wasson DB; Carson DA
J Med Chem; 1996 Jan; 39(1):2-9. PubMed ID: 8568809
[TBL] [Abstract][Full Text] [Related]
20. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
[No Abstract] [Full Text] [Related]
[Next] [New Search]
